RegulatoryJun 24, 2026, 09:02 AM
Femasys Regains Compliance with Nasdaq Minimum Bid Price Requirement
AI Summary
Femasys Inc. announced it has regained compliance with The Nasdaq Stock Market LLC's Listing Rule 5550(a)(2), the minimum bid price requirement, and that the matter is now closed. CEO Kathy Lee-Sepsick highlighted this as an important development for the company and its shareholders, allowing them to focus on strategic priorities and expanding access to innovative reproductive health solutions. Femasys continues to advance its fertility products like FemaSeed® and its FemBloc® permanent birth control, which received European, UK, and New Zealand regulatory approvals in 2025, with a U.S. FDA pivotal trial ongoing.
Key Highlights
- Femasys Inc. received formal notice from Nasdaq confirming regained compliance with Listing Rule 5550(a)(2).
- The Nasdaq minimum bid price requirement matter is now closed.
- CEO Kathy Lee-Sepsick stated the company will focus on advancing strategic priorities and expanding access to reproductive health solutions.
- Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination (ITI) and FemVue®.
- FemBloc® permanent birth control received full regulatory approval in Europe, the UK, and New Zealand in 2025.
- The FINALE pivotal trial (NCT05977751) for FemBloc® U.S. FDA approval is currently ongoing.
Price Impact
More from FEMY